Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL29355511 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL415972 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL2950056 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL29497289 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL30690015 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL2851348 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL4744369 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL29492949 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL179910 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Alfuzosin SCHEMBL4745192 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7585 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4739678-A2 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | Memorial Sloan Kettering Cancer Center (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260125647-A1 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-07 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3930839-B1 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | CARDIFF ONCOLOGY INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250367321-A1 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-04 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4608388-A1 | COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES FOR OBESITY AND OTHER DISEASES | STARROCK PHARMA INC. (US) | 2025-09-03 | — | — | EP | claimed |
| WO-1996030020-A1 | TRANSDERMAL DEVICE FOR THE DELIVERY OF ALFUZOSIN | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| US-5523094-A | Transdermal pharmaceutical composition | SYNTHELABO (FR) | 1996-06-04 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0582502-A1 | Transdermal composition containing alfuzosin | SYNTHELABO (FR) | 1994-02-09 | — | — | EP | claimed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0178961-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON DILTIAZEM AND ALFUZOSINE | SYNTHELABO (FR) | 1990-08-08 | — | — | EP | claimed |
| US-4925837-A | SYNERGISTIC COMBINATION OF ALPHA-BLOCKER AND CALCIUM ANTAGONIST; HYPOTENSIVE AGENTS | SYNTHELABO (FR) | 1990-05-15 | — | — | US | claimed |